Over-the-Counter Oral Contraceptive Pills September 14, 2023 Issue Brief Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.
The Health Wonk Shop: Probing the Legal Arguments in the Drug Industry’s Challenges to Medicare Drug Price Negotiations September 12, 2023 Event With the Biden administration’s announcement of the first 10 drugs to be negotiated for Medicare as part of the Inflation Reduction Act (IRA), an array of legal challenges from the pharmaceutical industry is potentially the biggest obstacle to implementation. In court filings, individual drugmakers and the industry’s main lobbying group…
Medicaid Utilization and Spending on New Drugs Used for Weight Loss September 8, 2023 Blog This brief discusses Medicaid coverage of weight-loss drugs, recent trends in Medicaid utilization and gross spending on new drugs used for weight loss, and the potential implications of those new drugs for Medicaid programs and enrollees.
The 4 Arguments You Will Hear Against Drug Price Negotiation September 6, 2023 Perspective As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF’s Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
Will Where You Live Determine Access and Coverage of Emerging Anti-Obesity Drugs? August 30, 2023 Blog The U.S. Midwest and South regions have higher average obesity rates among adults. What does this mean for access and coverage of prescription drugs for weight loss?
Public Opinion on Prescription Drugs and Their Prices August 21, 2023 Poll Finding This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries August 17, 2023 News Release In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs. Ozempic, which has been approved in the…
How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices? August 17, 2023 Issue Brief A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for…
KFF Tracking Poll July 2023: Substance Use Crisis And Accessing Treatment August 15, 2023 Poll Finding In the midst of an opioid epidemic in the United States, two-thirds of adults say either they or a family member have been impacted by drug or alcohol addiction. Three in ten say they or their family were addicted to prescription or illegal opioids. This survey explores treatments received by those who battled addiction, impacts of addiction, and support for policies aimed at reducing drug overdoses.
KFF Poll: Three-in-Ten People Say They or Someone in Their Family Has Been Addicted to Opioids, with Rural Families Hit Hardest August 15, 2023 News Release A new KFF poll assessing the broad reach of the nation’s opioids crisis on families across the United States reveals that three-in-ten adults (29%) say they or someone in their family have ever been addicted to opioids, including prescription painkillers and illegal drugs like heroin. Rural residents (42%) and White…